Pargyline: Difference between revisions
m Robot: Automated text replacement (-{{reflist}} +{{reflist|2}}, -<references /> +{{reflist|2}}, -{{WikiDoc Cardiology Network Infobox}} +) |
m Protected "Pargyline": Bot: Protecting all pages from category Drug ([Edit=Allow only administrators] (indefinite) [Move=Allow only administrators] (indefinite)) |
||
| (One intermediate revision by one other user not shown) | |||
| Line 1: | Line 1: | ||
{{drugbox | | {{drugbox | | ||
| IUPAC_name = ''N''-Benzyl-''N''-methyl-prop-2-yn-1-amine | | IUPAC_name = ''N''-Benzyl-''N''-methyl-prop-2-yn-1-amine | ||
| Line 26: | Line 25: | ||
| routes_of_administration = | | routes_of_administration = | ||
}} | }} | ||
__NOTOC__ | |||
{{SI}} | |||
{{CMG}} | |||
==Overview== | |||
'''Pargyline''' is a [[monoamine oxidase]] B (MAO-B) inhibitor. It functions by inhibiting the metabolism of [[catecholamines]] and [[tyramine]] within [[Chemical synapse|presynaptic nerve terminals]]. Patients taking pargyline must avoid concurrent consumption of [[tyramine]]-containing foods such as bleu cheese and [[beer]], as this can lead to a [[hypertensive]] crisis.<ref>Tulane University School of Medicine Department of Pharmacology: Autonomic Drug Profile handout, October 2006</ref> | |||
==References== | ==References== | ||
{{reflist|2}} | {{reflist|2}} | ||
[[Category:Monoamine oxidase inhibitors]] | [[Category:Monoamine oxidase inhibitors]] | ||
[[Category:Antihypertensive agents]] | |||
[[Category:Cardiovascular Drugs]] | |||
[[Category:Drug]] | |||
Latest revision as of 16:53, 20 August 2015
 | |
| Clinical data | |
|---|---|
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C11H13N |
| Molar mass | 195.69 g/mol |
|
WikiDoc Resources for Pargyline |
|
Articles |
|---|
|
Most recent articles on Pargyline |
|
Media |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Pargyline at Clinical Trials.gov Clinical Trials on Pargyline at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Pargyline
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Pargyline Discussion groups on Pargyline Directions to Hospitals Treating Pargyline Risk calculators and risk factors for Pargyline
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Pargyline |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pargyline is a monoamine oxidase B (MAO-B) inhibitor. It functions by inhibiting the metabolism of catecholamines and tyramine within presynaptic nerve terminals. Patients taking pargyline must avoid concurrent consumption of tyramine-containing foods such as bleu cheese and beer, as this can lead to a hypertensive crisis.[1]
References
- ↑ Tulane University School of Medicine Department of Pharmacology: Autonomic Drug Profile handout, October 2006
- Pages with script errors
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Chemical articles with unknown parameter in Infobox drug
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Monoamine oxidase inhibitors
- Antihypertensive agents
- Cardiovascular Drugs
- Drug